A tool that works in the first half-hour could reshape what stroke survival looks like
Por décadas, a barreira hematoencefálica resistiu às tentativas da medicina de proteger o cérebro nos momentos mais críticos. Pesquisadores da Universidade de Hong Kong desenvolveram um spray nasal de nanopartículas capaz de atravessar essa barreira e entregar agentes neuroprotetores diretamente ao tecido cerebral em minutos, sem agulhas ou cirurgia. Em estudos pré-clínicos, o uso do spray nos primeiros 30 minutos após um AVC reduziu o dano cerebral em mais de 80% — uma descoberta que pode redefinir o que significa chegar a tempo quando o cérebro está em risco.
- Mais de 85% dos pacientes com AVC isquêmico nunca recebem tratamento a tempo — por distância, por desconhecimento dos sintomas ou por não se enquadrarem nos critérios rígidos das terapias atuais.
- Cada minuto sem oxigênio dispara uma cascata de morte celular no cérebro, e os tratamentos existentes exigem janelas terapêuticas estreitas que a maioria das pessoas simplesmente não consegue alcançar.
- O spray nasal 'Nano-in-Micron' dissolve-se no muco nasal, libera nanopartículas que percorrem a via olfativa e chegam ao cérebro antes mesmo de uma ambulância ser acionada.
- Em modelos animais, o spray reduziu o infarto isquêmico em mais de 80% quando administrado dentro de 30 minutos — e pode ser aplicado por qualquer pessoa presente no momento do AVC.
- Os pesquisadores deixam claro: o spray não substitui o hospital, mas compra o tempo que pode ser a diferença entre recuperação e incapacidade permanente.
Uma equipe da Universidade de Hong Kong desenvolveu um spray nasal capaz de entregar medicamentos neuroprotetores diretamente ao cérebro sem cirurgia ou injeções — um avanço que enfrenta um dos maiores obstáculos da medicina moderna: a barreira hematoencefálica. A tecnologia, chamada de plataforma 'Nano-in-Micron', empacota nanopartículas dentro de um pó inalável. Ao entrar em contato com o muco nasal, o pó se dissolve e as nanopartículas percorrem a via olfativa até o tecido cerebral, entregando sua carga protetora em minutos.
O AVC isquêmico — causado por coágulos que bloqueiam o fluxo sanguíneo ao cérebro — é a segunda maior causa de morte e incapacidade no mundo. Os tratamentos existentes funcionam apenas dentro de uma janela de poucas horas, mas mais de 85% dos pacientes não chegam a tempo: vivem longe de hospitais, não reconhecem os sintomas ou não preenchem os critérios de elegibilidade. Mesmo quando tratados, mais da metade não recupera a função plena.
A professora Aviva Chow Shing-fung, que lidera a pesquisa, descreve o spray como uma ferramenta de intervenção pré-hospitalar: portátil, simples o suficiente para ser administrado por um familiar ou transeunte, e capaz de proteger as células cerebrais desde o primeiro momento do AVC. Além de entregar os medicamentos, o spray reduz a inflamação e interrompe o processo de morte celular programada que se alastra pelo tecido danificado.
Em estudos com animais, o uso do spray nos primeiros 30 minutos reduziu o dano cerebral em mais de 80%. O pesquisador Shao Zitong reforça que o objetivo não é substituir o atendimento hospitalar, mas criar uma ponte entre o momento do AVC e o acesso ao cuidado avançado — ampliando a janela terapêutica e aumentando as chances de sobrevivência com menos sequelas.
A team of researchers at the University of Hong Kong has created something that medicine has struggled with for decades: a way to get protective drugs into the brain quickly, without surgery or needles. It's a nasal spray made of nanoparticles—so small they can slip past the blood-brain barrier, that fortress-like membrane that normally blocks most medications from reaching brain tissue. When sprayed into the nose at the first sign of a stroke, the powder dissolves in nasal mucus and travels directly to the brain, delivering neuroprotective agents before a patient ever reaches a hospital.
The work comes from the Department of Pharmacology and Pharmacy at HKUMed, partnering with the Advanced Biomedical Instrumentation Centre. Over more than a decade, the team developed what they call the "Nano-in-Micron" platform—essentially a way to package tiny nanoparticles inside slightly larger powder particles that can be inhaled. When the powder hits the moist lining of the nose, it breaks apart, and the nanoparticles slip through to the brain. It sounds simple. It is not. Getting drugs across the blood-brain barrier has defeated researchers for years; more than 90 percent of candidate drugs targeting the central nervous system fail in clinical trials precisely because they cannot breach that barrier.
Stroke matters because it kills and disables more people worldwide than almost any other condition. Ischemic stroke—the kind caused by a blood clot blocking blood flow to the brain—is the second leading cause of death and disability globally. Yet the current treatments, which involve dissolving clots with medication or removing them mechanically, work only if administered within a narrow window, often just a few hours. The problem is brutal in its simplicity: more than 85 percent of stroke patients never receive treatment in time. Some live too far from hospitals. Some don't recognize the symptoms. Some arrive but don't meet the strict eligibility criteria. Even when treatment succeeds, more than half of patients don't recover full function.
According to Aviva Chow Shing-fung, an associate professor leading the research, the nasal spray changes the equation. It is fast—no waiting for an ambulance to arrive, no delay in the emergency room. It is portable; a family member or bystander could administer it. It is simple enough that almost anyone could use it. Most importantly, it buys time. By protecting brain cells from the moment of stroke onset, even before hospital treatment begins, the spray can slow the cascade of cell death that happens when the brain is starved of oxygen. In animal studies, when the spray was used within 30 minutes of stroke onset, it reduced brain damage by more than 80 percent.
The spray works through four steps. First, the micrometric powder is inhaled through the nose. It deposits in the nasal cavity. When it contacts the mucus lining, it breaks apart into nanoparticles. Those particles then travel along the olfactory pathway—the route from nose to brain—crossing the blood-brain barrier and delivering their cargo of neuroprotective agents directly into brain tissue. The spray does more than just deliver drugs; it also reduces inflammation in the brain and prevents cells from undergoing apoptosis, the programmed cell death that cascades through damaged tissue. The result is comprehensive protection: the brain's structure is preserved, its function is protected, and the window for subsequent hospital treatment is extended.
Researchers emphasize that this is not meant to replace hospital care. Shao Zitong, a postdoctoral researcher on the team, is clear on this point: the spray is a pre-hospital measure, a bridge between the moment a stroke happens and the moment a patient reaches advanced medical care. It works alongside existing systems, not instead of them. The goal is to intervene early enough to reduce the extent of brain damage and lower the risk of death or severe disability. For a condition where time is measured in minutes and outcomes are measured in lost function, a tool that works in the first half-hour—before the ambulance arrives, before the hospital doors open—could reshape what stroke survival looks like.
Notable Quotes
The spray allows patients to receive early protection on the way to the hospital or even at home, significantly slowing brain cell death and preserving viable brain tissue while gaining valuable time for subsequent treatments.— Aviva Chow Shing-fung, associate professor at HKUMed
This approach is not meant to replace existing hospital treatments, but to serve as an urgent pre-hospital support measure working alongside current medical systems.— Shao Zitong, postdoctoral researcher at ABIC
The Hearth Conversation Another angle on the story
Why does getting a drug into the brain during a stroke matter so much? Can't hospitals just give stronger medications?
The problem isn't strength; it's access. The blood-brain barrier blocks almost everything, including most drugs. And even if you could get a drug there, you'd need to wait for the ambulance, the hospital, the imaging, the decision. By then, brain cells are already dying. This spray works in the first 30 minutes, before any of that happens.
So the nanoparticles just float up through the nose to the brain?
Not float—they travel along the olfactory pathway, the same route that smell signals use. The nasal mucus dissolves the powder, releases the nanoparticles, and they cross the blood-brain barrier through a route that normally excludes most molecules. It's elegant because it uses a pathway the brain already has.
The animal studies showed 80 percent reduction in brain damage. What does that actually mean for a person?
It means fewer dead brain cells, preserved function. A stroke patient might regain movement, speech, cognition that would otherwise be lost. But these are animal studies. Human trials will tell us if that translates.
Why hasn't anyone done this before?
The blood-brain barrier is genuinely difficult. And engineering particles small enough to cross it but stable enough to deliver drugs—that took over a decade of work. Most researchers gave up. These scientists didn't.
If someone has a stroke at home, who administers the spray?
A family member, a bystander, anyone nearby. It's a nasal spray, like anything you'd buy at a pharmacy. The barrier to use is almost zero. That's the point.
What happens next?
Human trials. The pre-clinical work is done. Now they need to prove it works in actual stroke patients, that it's safe, that it doesn't interfere with hospital treatments. That's years away. But if it works, it changes the timeline of stroke care entirely.